Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

Shareholders in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.

Following the upgrade, the current consensus from Syros Pharmaceuticals' seven analysts is for revenues of US$19m in 2021 which - if met - would reflect an okay 6.2% increase on its sales over the past 12 months. Losses are expected to be contained, narrowing 16% from last year to US$1.35. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$11m and losses of US$1.75 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for Syros Pharmaceuticals

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Syros Pharmaceuticals' past performance and to peers in the same industry. We would highlight that Syros Pharmaceuticals' revenue growth is expected to slow, with the forecast 8.3% annualised growth rate until the end of 2021 being well below the historical 70% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Syros Pharmaceuticals.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Syros Pharmaceuticals is moving incrementally towards profitability. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. More bullish expectations could be a signal for investors to take a closer look at Syros Pharmaceuticals.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Syros Pharmaceuticals going out to 2025, and you can see them free on our platform here..

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

If you’re looking to trade Syros Pharmaceuticals, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

What are the risks and opportunities for Syros Pharmaceuticals?

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.